Approach to Fever of Unknown Origin in Clinical Practice

Abstract

Fever of unknown origin (FUO) remains a perplexing and challenging diagnostic entity in clinical medicine, characterized by prolonged fever without an identified cause despite thorough investigation. This review synthesizes current definitions, epidemiological trends, pathophysiological mechanisms, risk factors, clinical features, diagnostic algorithms, therapeutic strategies, recent advances, and guideline-based recommendations, with a focus on practical application for clinicians. Evidence from recent literature and consensus guidelines is integrated to facilitate a systematic and rational clinical approach to patients presenting with FUO.

Introduction

Fever of unknown origin has evolved as both a diagnostic challenge and a subject of intense clinical scrutiny. Defined classically by Petersdorf and Beeson in 1961 as temperature >38.3°C (101°F) on several occasions for at least three weeks, with no diagnosis after one week of inpatient investigation, FUO now encompasses broader categories including classic, nosocomial, neutropenic, and HIV-associated variants. This article delineates the contemporary approach to FUO, emphasizing evidence-based strategies for differential diagnosis, efficient workup, and optimal management within clinical practice.

Epidemiology / Disease Burden

FUO accounts for a small yet significant proportion of inpatient and outpatient evaluations, with an incidence estimated at 2-3% among hospitalized patients presenting with fever. The spectrum of etiologies has shifted over decades, with infections, malignancies, and non-infectious inflammatory diseases (NIIDs) remaining most prevalent. Geographic variations and advancements in diagnostic modalities have influenced disease patterns, with developing regions reporting higher infectious causes, while autoimmune and neoplastic etiologies predominate in high-income settings. The burden of undiagnosed cases persists, impacting patient morbidity, healthcare utilization, and resource allocation.

Pathophysiology

The mechanisms underlying FUO are diverse, reflecting the heterogeneity of underlying diseases. Fever arises from exogenous or endogenous pyrogens stimulating the hypothalamic thermoregulatory center, often via interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Infections trigger immune responses through pathogen-associated molecular patterns, whereas neoplasms may evoke fever through cytokine release or necrosis. NIIDs, such as vasculitides and connective tissue disorders, involve dysregulated immune activation. Drug fever and factitious disorders represent non-classical mechanisms, complicating the clinical picture.

Risk Factors

Risk stratification is pivotal in FUO evaluation. Epidemiological clues—age, travel history, exposure to animals, immunosuppression, and occupational risks—direct the etiological search. Immunocompromised individuals, such as those with HIV/AIDS, solid organ transplants, or hematological malignancies, are predisposed to opportunistic infections and atypical presentations. Age extremes (infants, elderly) may mask classic features. History of autoimmune disease, malignancy, or recent hospitalizations further increases the likelihood of specific FUO subtypes.

Clinical Features

FUO presents with persistent or intermittent fever, often accompanied by constitutional symptoms such as malaise, night sweats, weight loss, and myalgias. Organ-specific symptoms, when present, may provide diagnostic clues—arthritis, skin lesions, lymphadenopathy, or hepatosplenomegaly. A careful chronological history and thorough physical examination, repeated over time, are essential. Patterns of fever (quotidian, remittent, relapsing) and associated signs (rash, new murmurs, neurologic deficits) should be meticulously documented, as they may suggest particular etiologies (e.g., endocarditis, vasculitis, lymphoma).

Diagnosis

The diagnostic workup for FUO must be systematic, iterative, and hypothesis-driven. Initial investigations typically include complete blood count, inflammatory markers (ESR, CRP), liver and renal function tests, blood cultures, urinalysis, and chest radiography. Directed serologies (e.g., ANA, RF, HIV, TB testing), imaging (CT, MRI, PET-CT), and tissue biopsies are guided by clinical suspicion. Advanced molecular diagnostics (PCR, next-generation sequencing) are increasingly employed for elusive infections. Biopsy of accessible lesions (lymph nodes, liver, bone marrow) remains indispensable when malignancy or granulomatous diseases are suspected. The principle of avoiding empiric therapy before sufficient diagnostic sampling is paramount to prevent masking of underlying pathology.

Treatment & Management

Management of FUO is principally directed by the underlying etiology once identified. Empiric therapy is generally discouraged unless the patient is critically ill or neutropenic. Specific antimicrobial, immunosuppressive, or oncologic therapies are initiated upon diagnosis. Supportive care, including antipyretics and hydration, is essential. In cases where no cause is found, observation and symptomatic management may suffice, as a significant proportion of patients experience spontaneous resolution. Multidisciplinary collaboration—infectious disease, rheumatology, hematology, and oncology—is often required for complex cases.

Recent Advances / Emerging Therapies

Recent years have witnessed the advent of advanced imaging modalities such as FDG PET-CT, which improves localization of occult inflammatory or malignant foci. Molecular diagnostics, including multiplex PCR panels and metagenomic sequencing, have enhanced detection of rare pathogens. Biomarkers such as procalcitonin and ferritin assist in tailoring therapy and prognostication. Artificial intelligence and machine learning models are being explored to refine diagnostic algorithms, although their clinical utility remains investigational. Immunomodulatory agents and targeted therapies are increasingly used for refractory or autoimmune FUO subsets.

Guideline Recommendations

Consensus guidelines from the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) emphasize a structured approach: comprehensive history-taking, repeated physical examination, avoidance of premature empiric therapy, and judicious use of diagnostic tests. Routine application of PET-CT is endorsed for persistent cases with inconclusive conventional imaging. Biopsy is recommended for unexplained lymphadenopathy or organomegaly. Immunosuppressed patients require expedited evaluation and empiric antimicrobial coverage. Documentation of diagnostic reasoning and periodic case re-review are integral to the process.

Conclusion

Fever of unknown origin remains a formidable diagnostic challenge in modern clinical practice, demanding a systematic, evidence-based, and patient-centered approach. Advances in diagnostics and therapeutics have improved etiological yield and outcomes, yet a significant subset remains undiagnosed. Ongoing research, interdisciplinary collaboration, and adherence to evolving guidelines are essential for optimizing patient care and advancing understanding of this complex clinical syndrome.